Views & Analysis Access and elimination: the future of DAAs in hepatitis C How direct-acting antivirals are transforming treatment of hepatitis C.
News Gilead ordered to pay Merck & Co $2.54 bn by US court Ruling relates to infringement of patents held by Merck subsidiary
News AbbVie taking on Gilead with eight-week hep C course Latest combination drug resulted in 97.5% cure rates across all major disease strains
Debates & Insight Sponsored The hepatitis C conundrum: balancing cost and affordability An estimated 2–3% of the world’s population is living with hepatitis C virus (HCV) – a condition that, when left untreated, can cause life-threatening damage to the liver.
Views & Analysis Many millions still untreated – but hep C boom is already ov... Gilead has led a revolution in curing hepatitis C, but now faces a slowdown.
Oncology ASCO26: AI supercharging gene-based cancer detection, with D... Pharmaphorum caught up with Caris Life Science's David Spetzler to talk about how agentic AI is empowering whole genome sequencing in cancer detection
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
